NCT00853307 2022-04-08
MLN8237 for Treatment of Participants With Ovarian, Fallopian Tube, or Peritoneal Carcinoma
Takeda
Phase 2 Completed
Clinical Trials
17 trialsNCT02327169 2020-02-25
A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies
Takeda
Phase 1 Completed
NCT02259010 2019-09-20
A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Participants With Advanced Solid Tumors or Relapsed/Refractory Lymphoma
Takeda
Phase 1 Completed
NCT01898078 2019-06-21
Food Effect Study of Alisertib (MLN8237) in Participants With Advanced Solid Tumors or Lymphomas
Takeda
Phase 1 Completed
NCT01844583 2019-03-25
Safety, Tolerability and Pharmacokinetic (PK) of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib
Takeda
Phase 1 Completed
NCT00651664 2019-03-15
A Phase I Clinical and Pharmacodynamic Study of MLN8237, A Novel Aurora A Kinase Inhibitor, in Participants With Advanced Malignancies
Takeda
Phase 1 Completed
NCT01512758 2019-03-15
A Study of Alisertib (MLN8237) in Adult East Asian Participants With Advanced Solid Tumors or Lymphomas
Takeda
Phase 1 Completed
NCT00500903 2019-03-14
A Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Participants With Advanced Solid Tumors
Takeda
Phase 1 Completed
NCT00962091 2019-03-12
Study of MLN8237 in Participants With Advanced Solid Tumors
Takeda
Phase 1 Completed
NCT01094288 2019-02-15
A Phase 1 Study of Alisertib Participants With Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel Regimen
Takeda
Phase 1 Completed
NCT02214147 2018-11-15
Pharmacokinetics of Alisertib in Adults With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Function
Takeda
Phase 1 Completed
NCT01714947 2018-10-31
Mass Balance, Pharmacokinetics and Metabolism Study of Alisertib
Takeda
Phase 1 Completed
NCT01482962 2018-07-31
Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
Takeda
Phase 3 Completed
NCT01091428 2018-06-04
Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer
Takeda
Phase 2 Completed
NCT00807495 2018-03-27
Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma
Takeda
Phase 2 Completed
NCT01397825 2018-03-27
MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine
Takeda
Phase 1/2 Completed
NCT01045421 2016-08-15
Alisertib in Adults With Nonhematological Malignancies, Followed by Alisertib in Lung, Breast, Head and Neck or Gastroesophageal Malignancies
Millennium Pharmaceuticals, Inc.
Phase 1/2 Completed